{"id":"ef3b108789cc","type":"article","url":"https://hartvaat.nl/2020/11/07/colchicine-timing-en-cv-uitkomsten-na-mi-colcot-analyse/","title":"Colchicine timing en CV-uitkomsten na MI: COLCOT analyse","title_en":"Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["colcot-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaa659","source_url":"https://doi.org/10.1093/eurheartj/ehaa659","authors":["Nadia Bouabdallaoui","Jean-Claude Tardif","David D Waters","Fausto J Pinto","Aldo P Maggioni","Rafael Diaz","Colin Berry","Wolfgang Koenig","Jose Lopez-Sendon","Habib Gamra","Ghassan S Kiwan","Lucie Blondeau","Andreas Orfanos","Reda Ibrahim","Jean C Grégoire","Marie-Pierre Dubé","Michelle Samuel","Olivier Morel","Pascal Lim","Olivier F Bertrand","Simon Kouz","Marie-Claude Guertin","Philippe L L'Allier","Francois Roubille"],"significance":7,"published":"2020-11-07","source_date":"2020-11-07","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/colchicine-cardiovasculair/","https://hartvaat.nl/kennis/cardiometabool/bloedsuikerdoelen-cardiovasculair/"],"congress":"","summary_en":"This COLCOT analysis demonstrated that earlier initiation of colchicine after myocardial infarction is associated with greater cardiovascular benefit, supporting prompt anti-inflammatory therapy in the acute post-MI period.","created":"2026-07-03T10:28:52Z","updated":"2026-07-03T13:28:01Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"COLCOT analyse naar het verband tussen het tijdstip van colchicine-start en cardiovasculaire uitkomsten na MI.","abstract_original":"AIMS: The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the benefits of targeting inflammation after myocardial infarction (MI). We aimed to determine whether time-to-treatment initiation (TTI) influences the beneficial impact of colchicine. METHODS AND RESULTS: In COLCOT, patients were randomly assigned to receive colchicine or placebo within 30 days post-MI. Time-to-treatment initiation was defined as the length of time between the index MI and the initiation of study medication. The primary efficacy endpoint was a composite of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring coronary revascularization. The relationship between endpoints and various TTI (<3, 4-7 and >8 days) was examined using multivariable Cox regression models. Amongst the 4661 patients included in this analysis, there were 1193, 720, and 2748 patients, respectively, in the three TTI strata. After a median follow-up of 22.7 months, there was a significant reduction in the incidence of the primary endpoint for patients in whom colchicine was initiated < Day 3 compared with placebo [hazard ratios (HR) = 0.52, 95% confidence intervals (CI) 0.32-0.84], in contrast to patients in whom colchicine was initiated between Days 4 and 7 (HR = 0.96, 95% CI 0.53-1.75) or > Day 8 (HR = 0.82, 95% CI 0.61-1.11). The beneficial effects of early initiation of colchicine were also demonstrated for urgent hospitalization for angina requiring revascularization (HR = 0.35), all coronary revascularization (HR = 0.63), and the composite of cardiovascular death, resuscitated cardiac arrest, MI, or stroke (HR = 0.55, all P < 0.05). CONCLUSION: Patients benefit from early, in-hospital initiation of colchicine after MI. TRIAL REGISTRATION: COLCOT ClinicalTrials.gov number, NCT02551094."}